Worth reading
71In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
420000
¥Wording
Definitive
How definitive the wording is.Details of issuance or disposal
Issuance of Series 22 stock acquisition rights through a third-party allotment with an exercise price adjustment provision
Who receives how much
21,000,000 potential shares (210,000 stock acquisition rights; 100 common shares per stock acquisition right)
EVO FUND: 210,000 stock acquisition rights, 21,000,000 potential shares
The lower thin line represents the existing number of shares to which these shares will be added.
¥2 per stock acquisition right
Total issue value
¥420,000
Amount of funds to be raised
¥1,120,870,000 (estimated net proceeds after reflecting the total payment for these stock acquisition rights, the total exercise proceeds and issuance expenses; breakdown: Not disclosed)
Terms of the stock acquisition rights
Exercise price
Initial exercise price: ¥54. Subject to an adjustment clause. Minimum exercise price: ¥27. No maximum exercise price.
Exercise period
14 May 2026 to 13 April 2027
Number of Stock Acquisition Rights
Total number issued: 210,000. Number of unexercised rights remaining: Not disclosed.
Payment date
13 May 2026
Basis for determining the amount to be paid
The basis for calculating the issue price is Not disclosed in this disclosure. The initial exercise price is 100% of the closing price on 27 April 2026, and from the second adjustment onward, it is 100% of the simple average closing price for the 2 consecutive trading days preceding the adjustment date.
Most recent equity financing
Resolution dated 27 April 2026: issue of the 22nd Series of Stock Acquisition Rights through a private placement and the 2nd Series of Unsecured Corporate Bonds (privately placed bonds), among other matters. However, the details of the amounts are Not disclosed in the body of the disclosure.
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance of Series 22 stock acquisition rights through a third-party allotment with an exercise price adjustment provision |
| Number of shares to be issued or disposed of | 21,000,000 potential shares (210,000 stock acquisition rights; 100 common shares per stock acquisition right) |
| Issue price and disposal price | ¥2 per stock acquisition right |
| Total issue value | ¥420,000 |
| Amount of funds to be raised | ¥1,120,870,000 (estimated net proceeds after reflecting the total payment for these stock acquisition rights, the total exercise proceeds and issuance expenses; breakdown: Not disclosed) |
| Payment date | 13 May 2026 |
| Intended allottee | EVO FUND: 210,000 stock acquisition rights, 21,000,000 potential shares |
| Basis for determining the amount to be paid | The basis for calculating the issue price is Not disclosed in this disclosure. The initial exercise price is 100% of the closing price on 27 April 2026, and from the second adjustment onward, it is 100% of the simple average closing price for the 2 consecutive trading days preceding the adjustment date. |
| Exercise price | Initial exercise price: ¥54. Subject to an adjustment clause. Minimum exercise price: ¥27. No maximum exercise price. |
| Exercise period | 14 May 2026 to 13 April 2027 |
| Number of Stock Acquisition Rights | Total number issued: 210,000. Number of unexercised rights remaining: Not disclosed. |
| Most recent equity financing | Resolution dated 27 April 2026: issue of the 22nd Series of Stock Acquisition Rights through a private placement and the 2nd Series of Unsecured Corporate Bonds (privately placed bonds), among other matters. However, the details of the amounts are Not disclosed in the body of the disclosure. |
Items this document does not state (16)
Estimated issuance expensesSpecific use of fundsIntended allottee's holding policyDilution RateTotal number of issued sharesTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Payment of the issue price for the 22nd Series of Stock Acquisition Rights pursuant to the resolution of the Board of Directors dated 27 April 2026 was completed.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.